Bauhinia

Bauhinia: A Comprehensive Reference

1. Identity: Botanical Classification, Names, and Forms

Taxonomy and Classification

Bauhinia is a large genus of flowering plants in the subfamily Cercidoideae and tribe Bauhinieae, in the large flowering plant family Fabaceae, with a pantropical distribution. The genus was named by Carl Linnaeus in 1753 after the Swiss botanist brothers Johann (1541–1613) and Gaspard Bauhin (1560–1624), whose collaborative illustrations evoked the leaf morphology. The genus comprises approximately 160 accepted species of flowering plants, consisting primarily of shrubs and small trees, with some species being climbers.

These plants are characterized by their distinctive bilobed leaves, which are often compared to butterfly wings due to the deep cleft at the apex, and large, showy flowers with five petals that resemble orchids in color and form, ranging from white and yellow to purple and red. The genus is pantropical in distribution, occurring in seasonally dry tropical bushlands, woodlands, savannas, and coastal forests across Africa, Asia, Australia, and the Americas, with some species reaching elevations up to 3,200 meters.

Medically Relevant Species

Genus Bauhinia has been widely used in the treatment of diabetes, malaria, cough, headache, fever, piles, dysentery, flatulence, diarrhoea, ulcer, and cardiovascular problems. Among the many species of this genus, Bauhinia variegata, B. purpurea, B. championii, B. racemosa, and B. forficata are commonly used in traditional medicine and have been thoroughly investigated for their medicinal properties.

The most frequently studied species, with their common names and primary regions of use, include:

• Bauhinia variegata L. — Known in Hindi as kachnar or kanchanar, in English as mountain ebony or orchid tree. Many species are widely planted in the tropics as orchid trees, particularly in India, Sri Lanka, Vietnam, Nepal, and south-eastern China.
• Bauhinia purpurea L. — Known as kachnar in India and as pokok tapak kerbau in Malaysia. Bauhinia purpurea is a species of flowering plant used in several traditional medicine systems to cure various diseases.
• Bauhinia forficata Link — Commonly known as the Brazilian orchid tree, pata-de-vaca, or cow's hoof, it is a deciduous to semi-evergreen tree in the legume family Fabaceae, characterized by its bilobed leaves resembling butterfly wings or ox hooves, large white orchid-like flowers, and brown seed pods. The species was formally described by the German botanist Johann Heinrich Friedrich Link in 1821, based on specimens from Brazil.
• Bauhinia racemosa Lam. — A species investigated primarily for anti-inflammatory and antitumor properties.
• Bauhinia championii Benth. and Bauhinia strychnifolia Craib — Species with documented bioactivities investigated in South and Southeast Asian traditional medicine contexts.

Plant Morphology

Bauhinia trees typically reach a height of 6–12 m and their branches spread 3–6 m outwards. The lobed leaves are usually 10–15 cm across. The five-petaled flowers are 7.5–12.5 cm in diameter, generally in shades of red, pink, purple, orange, or yellow, and are often fragrant. The tree begins flowering in late winter and often continues to flower into early summer.

Within B. forficata, two subspecies are recognized: B. forficata subsp. forficata and B. forficata subsp. pruinosa (Vogel) Fortunato & Wunderlin. The nominate subspecies lacks prominent pruinosity, while subsp. pruinosa is distinguished by a waxy, frosted coating on its leaves and young branches, reflecting adaptations to drier habitats.

Common Dosage Forms and Preparations

Parts used medicinally include bark, leaves, flowers, roots, and seeds, depending on the species and tradition. Common preparation forms reported in research and traditional use include:

• Aqueous decoctions — Bark and leaf decoctions are among the most traditional preparations. The decoction of the root is used for expelling gases, flatulence, and griping pain from the stomach and bowel; the bark of the plant is used as an astringent in the treatment of diarrhea.
• Teas (infusions and decoctions of dried leaves) — The tea prepared with their leaves has been extensively used in Brazilian traditional practices for the treatment of diabetes.
• Hydroalcoholic/ethanolic extracts — Used in experimental and clinical research, including standardized capsule preparations.
• Standardized capsule extracts — A double-blind, randomized clinical trial used capsules containing granules prepared by wet granulation of a standardized extract from B. forficata leaves.
• Classical Ayurvedic polyherbal formulations — The formulation Kanchanar Guggulu combines the bark of Kanchanara (Bauhinia variegata) with Guggulu (Commiphora mukul) and synergistic herbs known for their anti-inflammatory, detoxifying, and decongestant properties.
• Bark powders and poultices — Used topically for wounds and skin conditions in South Asian traditions.

2. Traditional and Historical Use

Ayurveda (India)

Bauhinia variegata (kanchanara) is categorized in the Charaka Samhita under Vamanopaga — a group of herbs useful in Vamana Panchakarma therapy (emesis) — and in the Sushruta Samhita under Kashayavarga, the group of astringent-tasting herbs. Since ancient times, tribal peoples have used plants from the Bauhinia genus extensively to treat a variety of therapeutic indications. Ayurveda and Traditional Chinese Medicine also acknowledge the medicinal benefits of these plants.

The herb is classified by taste (Kashaya — astringent), quality (Laghu — light to digest, Rooksha — dryness), a post-digestive taste conversion (Vipaka) to Katu (pungent), and cold potency (Veerya — Sheeta). Its special classical effect (Prabhava) is noted as useful in cervical lymphadenitis and thyroid complications.

The bark and buds of the tree are described as alterative and astringent. For treating leprosy, scrofula, ulcers, and other skin diseases, a decoction of the bark is administered. In scrofulous enlargements of cervical glands, the bark powder is given with dried ginger powder and rice water.

Kanchanar Guggulu is a Guggulu-based tablet preparation used as a herbal Ayurvedic medicine in the treatment of cysts, certain types of tumors, goitre, menstrual disorders, wound healing, and various skin diseases.

Traditional Use in South and Southeast Asia

B. purpurea, known to the Malays as pokok tapak kerbau, has been traditionally used by Indian, Sri Lankan, and Pakistani people to treat ailments like ulcers, wounds, glandular swellings, and stomach tumors. The bark or root mixed with flower and boiled rice water is used as a maturant for boils and abscesses.

The young pods and mature seeds of kachnar are known to be cooked and eaten by tribal communities such as the Kathkors and Gondas of India. The leaves are used as food and fodder during lean seasons, the bark is used as a fiber, dye, and tannin extract, and its decoction is used as an anthelmintic.

B. variegata and B. purpurea are widely used for the treatment of diabetes in nations such as India, China, Malaysia, Brazil, Pakistan, Sri Lanka, and Bangladesh.

Traditional Use in Brazil and South America

Bauhinia forficata is the Bauhinia species most used as an antidiabetic herbal remedy in Brazil, where it is known as "pata de vaca" (cow's hoof). This species is an arboreal plant of Asiatic origin which adapted well to the Brazilian climate, reaching 12 m in height. The first reports of Bauhinia forficata hypoglycemic activity in diabetic patients were made by Juliani in 1929 and 1931. Its use for blood sugar management is so well-established in Brazilian folk medicine that Bauhinia forficata has the highest number of studies regarding hypoglycemic activity among Bauhinia species and is included in the Medicinal Plants List of the Brazilian Public Health System.

Traditional Chinese Medicine

About 600 species of the genus Bauhinia are mainly distributed in tropical regions with 40 of them in China. Bauhinia brachycarpa Wall, a special plant of the genus, was used as a folk medicine for analgesia in southern provinces of China. Additional species, including B. championii, have been investigated within the context of Traditional Chinese Medicine for their anti-inflammatory and analgesic properties.

Breadth of Traditional Indications

Across all traditions, traditional uses encompass treatment of ailments like ulcers, wounds, glandular swellings, diarrhoea, dysentery, diabetes, jaundice, leprosy, rheumatism, and stomach tumors.

3. Key Constituents and Active Compounds

Flavonoids — The Primary Bioactive Class

A total of 164 flavonoids isolated from the genus Bauhinia have been reviewed, and biological activities including antidiabetic, anti-cancer, antibacterial, cytotoxicity, antidiarrheal, antioxidant, anti-inflammatory, and anti-cataract were all reported. The vast majority of the species in this genus possess interesting biological activities, and they are good sources of flavonoids, which are known to elicit excellent pharmacological properties and are well-positioned as potential drug candidates.

Among the flavonoid aglycones identified in the Bauhinia genus, kaempferol and quercetin have the highest occurrence among flavonols. Flavanols like catechin and fisetinidol had the highest occurrence in their sub-class, while naringenin, liquiritigenin, eriodictyol, and farrerol occurred most among flavanones.

A novel compound, 6-butyl-3-hydroxyflavanone, was reported from B. purpurea. Luteolin, myricetin, and 5,7,3′,4′,5′-pentamethoxyflavone are phytochemicals that occurred mostly among the flavones in the genus.

From the chemical point of view, the main components identified in the hydroalcoholic extract of the leaves of B. forficata are O-glycosylated derivatives of kaempferol and quercetin.

Other Major Chemical Constituents

A wide range of chemical compounds have been identified, including 5,6-dihydroxy-7-methoxyflavone 6-O-β-D xylopyrano-side, bis[3′,4′-dihydroxy-6-methoxy-7,8-furano-5′,6′-mono-methylalloxy]-5-C-5-biflavonyl, and bibenzyls, dibenzooxepins, a mixture of phytol fatty esters, lutein, β-sitosterol, isoquercitin, and astragalin.

Phytochemicals found in all parts of the tree — including flowers, stem, seed, root, bark, and leaves — include flavonoids, tannins, kaempferol, terpenoids, saponins, cardiac glycosides, and quercetin.

Compounds including resveratrol, epicatechin, quercetin, and gallic acid have been identified in some Bauhinia species.

Of particular note are the bauhiniastatins — antineoplastic compounds designated bauhiniastatins-1 through 4, isolated from Bauhinia purpurea.

D-pinitol, a cyclitol compound, has also been identified as one of the active principles of Bauhinia holophylla leaf extracts relevant to diabetes treatment.

LC-MS analysis of Bauhinia strychnifolia confirmed the existence of 3,5,7,3′,5′-pentahydroxyflavanonol-3-O-α-L-rhamnopyranoside and β-sitosterol in the extracts, with anticancer and antioxidant bioactivities.

Mechanisms of Action

Although some contradicting evidence has been documented, in general, results support the reported therapeutic properties of Bauhinia, indicating that they are mainly due to the presence of flavonoids. Plants of the genus, commonly known as cow's-paw or cow's hoof, have been used frequently in folk medicine to treat different kinds of pathologies, particularly diabetes, infections, as well as pain and inflammation.

The antidiabetic mechanism has been investigated at multiple levels. Rutin can reduce carbohydrate absorption by inhibiting α-glucosidase enzyme, kaempferol can enhance glucose uptake, and luteolin can inhibit lipid synthesis. Both quercetin and kaempferol inhibit α-amylase activity in vitro. The α-glucosidase inhibitory potential of fisetinidol and guibourtinidol, isolated from B. pulchella, showed excellent inhibitory activity with IC₅₀ values of 0.51 and 3.67 µg/mL, which are better than acarbose (positive control) at an IC₅₀ value of 45.72 µg/mL.

Multiple Bauhinia species have exhibited antidiabetic properties in mice and rats, demonstrating the potential of Bauhinia as a significant source of bioactive metabolites.

In terms of antimicrobial mechanisms, kaempferol and quercetin can bind to DNA helicase and inhibit its ATPase activity. Another strategy of antimicrobial activity is associated with bacterial membrane disruption. Flavonoids can inhibit bacterial growth by membrane rupture and permeabilization, direct interaction with membrane proteins, uncontrolled ROS generation, and inhibition of membrane and cell wall biosynthesis.

The cancer-preventive activities of various phytochemicals from Bauhinia lie in their ability to affect cellular defenses like detoxification, scavenging reactive oxygen species (ROS), as well as induction of antitumor and anti-inflammatory responses.

4. Scientific Evidence by Area of Use

4.1 Diabetes and Glycemic Control

This is the most extensively studied pharmacological area for genus Bauhinia. Evidence spans traditional documentation, preclinical animal studies, and a small number of human clinical trials.

Preclinical (Animal / In Vitro) Evidence

Preclinical studies have confirmed the hypoglycemic effect and antidiabetic activity of the hydroalcoholic extract of the leaves of B. forficata. Studies carried out with Bauhinia manca, Bauhinia divaricata, Bauhinia purpurea, and Bauhinia variegata have also demonstrated hypoglycemic activity in laboratory animals.

In one animal study of B. holophylla, an extract (200 or 400 mg/kg body weight) was administered for 14 days to streptozotocin-induced diabetic Swiss mice, with evaluation of glucose tolerance, insulin sensitivity, blood parameters, gene and protein expression, and in vivo and in vitro inhibition of intestinal glucosidases. HPLC-PAD-ESI-IT-MS analysis identified flavonoid derivatives of quercetin, myricetin, luteolin, and kaempferol in the extract.

Oral supplementation of quercetin and kaempferol — the key flavonoids in Bauhinia — significantly reduced blood glucose levels (p < 0.001), improved lipid profile (p < 0.001), and enhanced total antioxidant status (p < 0.01) in streptozotocin–nicotinamide-induced diabetic mice.

Antidiabetic extracts of B. forficata were tested in alloxan-induced diabetic rats at doses of 200 and 400 mg/kg, administered orally daily for 7 days, 48 hours after alloxan injection.

Human / Clinical Evidence

The search for evidence of the alleged anti-diabetic activity of B. forficata at the clinical level was performed in only two earlier studies, both with few patients and questionable methodological quality, that used tea as a pharmaceutical form — a fact that raises questions about dose reproducibility.

A more methodologically rigorous clinical trial was subsequently conducted. A double-blind, randomized clinical trial used capsules containing granules prepared by wet granulation of a standardized extract from B. forficata leaves as an adjuvant treatment. Ninety-two patients aged 18–75 years with type 2 diabetes were randomly assigned in a 1:1 ratio to receive capsules of B. forficata or placebo for four months.

A separate quasi-experimental lipid profile study in type 2 diabetic patients used a tea preparation: Twenty-five type 2 diabetic volunteer patients (mean age 62 years) were recruited. Participants drank the tea of 0.4% B. forficata in 200 mL of water twice a day for 3 months. The clinical parameters evaluated were cholesterol, triglycerides, total cholesterol, weight, postprandial glycemia, and glycosylated hemoglobin (HbA1c). Statistically significant decreases in triglycerides and total cholesterol levels of 48 and 17 mg/dL, respectively, were observed. However, the absence of a control group limits the interpretation of these findings.

Systematic Review Conclusion

The findings from a systematic review examining the adjuvant effect of Bauhinia forficata in the treatment of adults with type 2 diabetes mellitus suggest that B. forficata may be effective in improving glycaemia control, but the evidence should be interpreted with caution due to its preliminary nature. Additional RCTs of sufficient duration and sample size are indicated to determine the effects on HbA1c%, blood glucose, and other physiological parameters.

Evidence strength — Antidiabetic: Moderate preclinical evidence; very limited and preliminary human clinical evidence. No robust, adequately powered RCTs with definitive conclusions are yet available.

4.2 Anti-Inflammatory and Analgesic Activity

Bauhinia purpurea has been known to possess analgesic and anti-inflammatory activity across multiple experimental models. Research published in the Journal of Ethnopharmacology has investigated antinociceptive, anti-inflammatory, and antipyretic properties of B. purpurea aqueous leaf extracts in experimental animals.

A study on Bauhinia acuminata evaluated anti-nociceptive activity: The anti-nociceptive activity was evaluated in Swiss albino mice by hot plate, acetic acid-induced writhing, and tail immersion tests at three different dose levels (250, 500, and 1000 mg/kg) of aqueous and alcoholic extracts.

Evidence strength — Anti-inflammatory / analgesic: Entirely preclinical (animal and in vitro). No human clinical trials have been published. Evidence is preliminary.

4.3 Antioxidant Activity

Bauhinia species engender a diverse array of activities including antioxidant properties as part of a broader pharmacological profile. The antioxidant activity of extracts has been compared with standard antioxidants. Dose-dependent response was observed in reducing power of extracts. Polar extracts demonstrated appreciable metal ion chelating activity at lower concentrations (10–40 µg/mL), and many extracts showed significant antioxidant response in a beta-carotene bleaching assay.

Extracts from B. strychnifolia exhibited moderate antioxidant activity and increased glutathione (GSH) production in HepG2 cell lines compared with untreated controls.

Evidence strength — Antioxidant: In vitro evidence only. No human clinical trials.

4.4 Anticancer / Cytotoxic Activity

The aqueous (AQ) fraction of B. variegata showed pronounced cytotoxic effect against DU-145, HOP-62, IGR-OV-1, MCF-7, and THP-1 human cancer cell lines with 90–99% cell growth inhibitory activity. Ethyl acetate fraction also produced considerable cytotoxicity against MCF-7 and THP-1 cell lines. This demonstrates notable anticancer activities in B. variegata in vitro.

Studies showed that Bauhinia strychnifolia Craib dichloromethane and ethanol extracts possess strong anticancer activity against A549 (lung), KB3-1 (cervical), MDA-MB-231 (breast), and SW480 (colon) cancer cell lines via MTT assay. Extracts were also found to inhibit the growth of human hepatocellular carcinoma (HepG2) and colon adenocarcinoma (HT-29) cell lines.

The discovery of bauhiniastatins — cytotoxic compounds unique to this genus — is notable: Bauhiniastatins 1–4 were isolated from Bauhinia purpurea and identified as antineoplastic agents.

Evidence strength — Anticancer: In vitro (cell line) evidence only. No human clinical studies exist. Results cannot be extrapolated to human cancer treatment.

4.5 Antimicrobial Activity

Extracts from B. strychnifolia inhibited the growth of gram-positive bacteria Staphylococcus aureus and Bacillus cereus, but did not inhibit the growth of gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa.

Minimum bactericidal concentration (MBC) values of potential extracts were found between 3.5 and 28.40 mg/mL. The lowest MBC (3.5 mg/mL) was recorded for ethanol extract against Pseudomonas spp.

Evidence strength — Antimicrobial: In vitro only. Species-specific results vary considerably. No human clinical evidence.

4.6 Anthelmintic Activity

Extracts of flower of Bauhinia purpurea L. exhibit moderate to significant anthelmintic activity at the dose of 50–250 µg/mL. All the extracts were tested for anthelmintic activity using piperazine citrate as a reference standard. All tested extracts showed mild to moderate anthelmintic activity, with ethyl acetate (EtOAc) and methanol (MeOH) extracts found to be the most active agents among the extracts.

Evidence strength — Anthelmintic: In vitro experimental models only. No human evidence.

4.7 Thyroid-Regulating Activity

This is a traditional use area specific primarily to Bauhinia variegata in Ayurvedic practice, where the primary traditional application targets nodular and glandular swellings, especially in the thyroid and lymphatic system. Decoctions and extracts have been used to manage goitre nodules.

Research in animal models has investigated this property: Withania somnifera and Bauhinia purpurea were studied in the regulation of circulating thyroid hormone concentration in female mice.

Evidence strength — Thyroid regulation: Traditional use well-documented; animal model studies exist, but no published, peer-reviewed human clinical trials have established efficacy for thyroid conditions.

4.8 Antifungal Activity

A study evaluated the floral ethanolic extract of B. variegata, B. forficata, and B. purpurea in fungal inhibition against Sclerotinia sclerotiorum, Colletotrichum gloeosporioides, and Colletotrichum acutatum. Flowers were harvested in 2021 and 2022, and the floral ethanolic extract was produced by the static maceration method with the antifungal activity performed by agar diffusion. Bauhinia floral extracts showed a potential fungicidal effect on the fungal species evaluated, particularly for Sclerotinia sclerotiorum.

Evidence strength — Antifungal: In vitro evidence only. No human evidence.

4.9 Nephroprotective Activity

Bauhinia purpurea has been reported to possess nephroprotective activity in preclinical studies, in addition to its antibacterial, antidiabetic, analgesic, anti-inflammatory, anti-diarrheal, and anticancerous properties. All nephroprotective evidence is from animal models; no human clinical data are available.

5. Body Systems and Health Areas Associated with Bauhinia

Documented pharmacological activities of Bauhinia species include anti-diabetic, anti-microbial, antioxidant, anti-arthritic, cardioprotective, hepatoprotective, nephroprotective, fibrinolytic, and wound healing properties, and most of the biological activities correlate with traditional knowledge.

• Endocrine / Metabolic system: Antidiabetic (glycemic control, lipid modulation) — best-evidenced area.
• Lymphatic and glandular system: Traditional use for glandular swellings, goitre, lymphadenopathy (Ayurvedic tradition).
• Gastrointestinal system: Antidiarrheal, anthelmintic, astringent effects; bark used in traditional management of diarrhea, dysentery, flatulence.
• Immune and inflammatory system: Anti-inflammatory, antioxidant, and antimicrobial effects documented preclinically.
• Oncology (experimental): Cytotoxic activity in multiple cancer cell lines; bauhiniastatin compounds identified as antineoplastic in vitro.
• Renal system: Nephroprotective activity in animal models.
• Hepatic system: Hepatoprotective activity documented in some species.
• Musculoskeletal: Analgesic activity in experimental models; traditional use for rheumatism.
• Integumentary (skin): Topical use for ulcers, wounds, leprosy, and abscesses.

6. Dosages Reported in Studies

The following dosages are derived directly from published research and are specific to the contexts in which they were studied. They should not be interpreted as dosage recommendations.

• Standardized capsule extract (B. forficata, type 2 diabetes RCT): Capsules containing granules from a standardized extract of B. forficata leaves, administered as an adjuvant treatment to 92 patients for four months. (Exact mg dose not specified in the available abstract.)
• Tea preparation (B. forficata, lipid profile study): 0.4% B. forficata in 200 mL of water, administered twice a day for 3 months.
• Animal model doses (B. forficata extracts): 200 and 400 mg/kg, administered orally daily for 7 days, 48 hours after alloxan injection.
• Animal model doses (B. acuminata, antinociceptive): Three dose levels of 250, 500, and 1000 mg/kg of aqueous and alcoholic extracts in Swiss albino mice.
• In vitro anthelmintic (B. purpurea flower extract): 50–250 µg/mL.

7. Safety Considerations

Acute Toxicity Studies

Both aqueous and alcoholic extracts of B. acuminata were found safe at a dose of 5000 mg/kg in acute toxicity testing in mice.

Following acute oral administration of 2500 mg/kg crude extracts of Bauhinia variegata to Swiss albino mice, no mortalities or evidence of adverse effects were observed. The results indicated that the crude extracts of Bauhinia variegata did not show toxicity.

For B. cheilantha, in acute toxicity testing, administration of a single oral dose of the hydroalcoholic extract did not produce mortality or any toxic signs or symptoms at the different doses studied. No skin irritation, fur, eyes, or mucous membrane toxic effects; piloerection, disorientation, hypoactivity, hyperventilation, asthenia, lethargy, sleep, diarrhea, tremors, salivation, convulsion, coma, motor activity, or death were registered.

Subacute Toxicity and Long-Term Safety Gaps

The general perception that plants are absent from adverse effects due to their natural, nutritional, or medicinal importance is erroneous. Information on safe doses and prolonged use of Bauhinia species is still scarce. Further toxicity studies over a longer period of time involving detection of effects on vital organ functions are needed to ensure that the plants are safe.

Potential Mutagenicity of Key Flavonoids

Studies highlight that prolonged ingestion of flavonoids such as quercetin and kaempferol may result in mutagenicity and DNA damage, particularly in interaction with copper ions, suggesting a possible pro-oxidant activity of these compounds at high doses.

Literature data demonstrate that substances in medicinal preparations may have toxic effects, including DNA damage. The detection and evaluation of potential damages caused by plant compounds are of fundamental importance for minimizing adverse effects of plant extracts, especially when used in long-term treatments.

Additive Hypoglycemic Interactions

Because Bauhinia species — particularly B. forficata — demonstrate preclinically confirmed hypoglycemic activity, concurrent use with antidiabetic medications (insulin, metformin, sulfonylureas, etc.) represents a plausible interaction risk that warrants monitoring. Studies related to safety pharmacology and pharmacokinetic herb–drug interactions are especially important when concurrent use of herbal and modern medicine is rising. For chronic diseases including diabetes and cardiovascular conditions where long-term treatment is needed, co-administration of herbal and modern medicines may pose a higher risk of adverse events.

Phytochemical Variability

The phytochemical variations and efficacy of the medicinal values of B. purpurea are dependent on geographical location. This variability makes standardization of preparations critical for consistent and safe use, and complicates cross-study comparisons.

Bauhinia is a complex botanical genus, and the indiscriminate use of the diverse Bauhinia species is reflected in the experimental divergence of their medicinal potential. Species identification is therefore an important consideration, as the chemical composition, bioactivity, and safety profile can differ substantially among species marketed under the same common name ("cow's hoof," "pata-de-vaca," etc.).

Absence of Formal Regulatory Monographs

As of the time of this writing, the genus Bauhinia does not appear in European Medicines Agency (EMA), WHO, or Commission E pharmacopeial monographs dedicated to the genus as a whole. These Bauhinia species and the quantification of their individual phytoconstituents, as well as their pharmacological profiles based on in vitro, in vivo studies, and clinical trials, should be further investigated. The overall evidence base remains primarily preclinical, and the transition to rigorous clinical evaluation is still in early stages.

References

• Flavonoid in All Their Therapeutic Values: An Odyssey into the Phytochemistry and Pharmacology of Naturally Occurring Flavonoid from Genus Bauhinia — PMC / PubMed Central
• Chemical composition and biological potential of plants from the genus Bauhinia — PubMed
• Phytochemistry and pharmacological activities of five species of Bauhinia genus: A review — ScienceDirect (Fitoterapia, 2024)
• Evaluation of the effects of Bauhinia forficata as an adjuvant in the treatment of type 2 diabetes mellitus: Systematic review and meta-analysis — ScienceDirect
• Anti-diabetic activity of Bauhinia forficata decoction in streptozotocin-diabetic rats — ScienceDirect (Journal of Ethnopharmacology, 2002)
• Acute toxicity study and anti-nociceptive activity of Bauhinia acuminata Linn. leaf extracts — ScienceDirect (Biomedicine & Pharmacotherapy, 2018)
• Bauhinia Forficata in Diabetic Patients — ClinicalTrials.gov (NCT02760017)
• Effects of Bauhinia forficata Link Tea on Lipid Profile in Diabetic Patients — Journal of Medicinal Food (2019)
• Clinical efficacy of capsules containing standardized extract of Bauhinia forficata Link as adjuvant treatment in type 2 diabetes patients: A randomized, double-blind clinical trial — ScienceDirect (Biomedicine & Pharmacotherapy, 2021)
• Hypoglycaemic activity of Bauhinia holophylla through GSK3-β inhibition and glycogenesis activation — PMC
• Flavonoids and Phenols, the Potential Anti-Diabetic Compounds from Bauhinia strychnifolia Craib. Stem — PMC
• Bioactivity and Therapeutic Potential of Kaempferol and Quercetin: New Insights for Plant and Human Health — PMC
• Quercetin and Kaempferol as Multi-Targeting Antidiabetic Agents against Mouse Model of Chemically Induced Type 2 Diabetes — PMC
• Bauhinia variegata Leaf Extracts Exhibit Considerable Antibacterial, Antioxidant, and Anticancer Activities — PMC (BioMed Research International, 2013)
• Antiproliferative, antibacterial, and antioxidant activities of Bauhinia strychnifolia Craib aqueous extracts — PMC
• Safety assessment of Bauhinia cheilantha Bong. Steud. leaves extract: acute, sub-acute toxicity, antioxidant, and antihemolytic evaluations — PMC
• Phytochemical study and evaluation of cytotoxicity, mutagenicity, cell cycle kinetics and gene expression of Bauhinia holophylla in HepG2 cells — PMC
• Isolation of Phytochemicals from Bauhinia variegata L. Bark and Their In Vitro Antioxidant and Cytotoxic Potential — PMC
• Bauhinia purpurea Linn.: A Review of its Ethnobotany, Phytochemical and Pharmacological Profile — Research Journal of Medicinal Plants (SciAlert, 2011)
• Bauhinia — Wikipedia (for nomenclature and taxonomy context)
• Bauhinia variegata L. — World Flora Online (Royal Botanic Gardens, Kew)